Continuous-wave (CW) transscleral cyclophotocoagulation (TSCPC) is a method of treating glaucoma that involves cycloablation of the ciliary body epithelium to decrease the production of aqueous humour by the ciliary body, thereby lowering IOP.1
TSCPC is a safe and effective treatment modality we can utilise at all disease stages of glaucoma, whether as a standalone procedure or in conjunction with standard treatment therapies including minimally invasive glaucoma surgery (MIGS) or trabeculectomy.
The technique micropulse TSCPC utilises a different delivery modality than its predecessor, CW laser cycloablation, to produce a biological reaction without the lethal effects caused by thermal buildup. Despite a gentler laser application, the treatment remains efficacious at lowering IOP.
The micropulse laser works by chopping the laser beam into a train of repetitive short pulses, allowing the tissue to cool between pulses and preventing thermal elevation.
I recently participated in a study evaluating the safety and efficacy of this laser in patients with mild to moderate glaucoma. The retrospective cohort study reviewed the charts of 95 consecutive glaucoma patients who received micropulse TSCPC.